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The Desmoteplase in Acute Ischemic Stroke Trial (DIAS)
A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial
With Intravenous Desmoteplase
Werner Hacke, MD; Greg Albers, MD; Yasir Al-Rawi, MD; Julien Bogousslavsky, MD;
Antonio Davalos, MD; Michael Eliasziw, PhD; Michael Fischer, PhD; Anthony Furlan, MD;
Markku Kaste, MD; Kennedy R. Lees, MD; Mariola Soehngen, MD; Steven Warach, MD;
for The DIAS Study Group
Background and Purpose—Most acute ischemic stroke patients arrive after the 3-hour time window for recombinant tissue
plasminogen activator (rtPA) administration. The Desmoteplase In Acute Ischemic Stroke trial (DIAS) was a
dose-finding randomized trial designed to evaluate the safety and efficacy of intravenous desmoteplase, a highly
fibrin-specific and nonneurotoxic thrombolytic agent, administered within 3 to 9 hours of ischemic stroke onset in
patients with perfusion/diffusion mismatch on MRI.
Methods—DIAS was a placebo-controlled, double-blind, randomized, dose-finding phase II trial. Patients with National
Institute of Health Stroke Scale (NIHSS) scores of 4 to 20 and MRI evidence of perfusion/diffusion mismatch were
eligible. Of 104 patients, the first 47 (referred to as Part 1) were randomized to fixed doses of desmoteplase (25 mg,
37.5 mg, or 50 mg) or placebo. Because of an excessive rate of symptomatic intracranial hemorrhage (sICH), lower
weight-adjusted doses escalating through 62.5 g/kg, 90 g/kg, and 125 g/kg were subsequently investigated in 57
patients (referred to as Part 2). The safety endpoint was the rate of sICH. Efficacy endpoints were the rate of reperfusion
on MRI after 4 to 8 hours and clinical outcome as assessed by NIHSS, modified Rankin scale, and Barthel Index at 90
days.
Results—Part 1 was terminated prematurely because of high rates of sICH with desmoteplase (26.7%). In Part 2, the sICH
rate was 2.2%. No sICH occurred with placebo in either part. Reperfusion rates up to 71.4% (P0.0012) were observed
with desmoteplase (125 g/kg) compared with 19.2% with placebo. Favorable 90-day clinical outcome was found in
22.2% of placebo-treated patients and between 13.3% (62.5 g/kg; P0.757) and 60.0% (125 g/kg; P0.0090) of
desmoteplase-treated patients. Early reperfusion correlated favorably with clinical outcome (P0.0028). Favorable
outcome occurred in 52.5% of patients experiencing reperfusion versus 24.6% of patients without reperfusion.
Conclusions—Intravenous desmoteplase administered 3 to 9 hours after acute ischemic stroke in patients selected with
perfusion/diffusion mismatch is associated with a higher rate of reperfusion and better clinical outcome compared with
placebo. The sICH rate with desmoteplase was low, using doses up to 125 g/kg. (Stroke. 2005;36:66-73.)
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Outcome after acute ischemic stroke (AIS) is improved byIV thrombolysis with recombinant tissue plasminogen
activator (rtPA), which is the only approved drug for AIS.
However, the use of IV rtPA is currently limited by the need
to administer it within 3 hours of symptom onset.1 Clinical
trials investigating IV thrombolytics in AIS in later time
windows (Alteplase Thrombolysis for Acute Noninterven-
tional Therapy in Ischemic Stroke [ATLANTIS], European
Cooperative Acute Stroke Study [ECASS], and ECASS II)
have failed to show a significant benefit beyond 3 hours. A
pooled analysis of these trials suggests a benefit up to 270
minutes, but not up to 6 hours.2–5 A wider time-to-treatment
window may be achievable using a thrombolytic drug with a
better safety and efficacy profile in patients selected by
modern MRI technology, which, for clinical purposes, may
identify ischemic penumbra.
Received August 11, 2004; final revision received September 21, 2004; accepted October 6, 2004.
From the Department of Neurology (W.H.), University of Heidelberg, Heidelberg; PAION GmbH (Y.A.-R., M.S.), Aachen; ClinResearch GmbH
(M.F.), Ko¨ln, Germany; Centre Hospitalier Universitaire Vaudois (J.B.), Department of Neurology, Lausanne, Switzerland; Hospital Universitari Dr Josep
Trueta (A.D.), Girona, Spain; the University of Calgary (M.E.), Heritage Medical Research Building. Calgary, Alberta, Canada; Helsinki University
Central Hospital (M.K.), Department of Clinical Neurosciences, Helsinki, Finland; Western Infirmary (K.R.L.), University Department, of Medicine &
Therapeutics, Glasgow, United Kingdom; the Stanford Stroke Center (G.A), Palo Alto, Calif; the Cleveland Clinic Foundation (A.F.), Department of
Neurology, Cleveland, Ohio; and the National Institute of Neurological Disorders and Stroke (S.W.), Bethesda, Md.
Correspondence to Dr Werner Hacke, Department of Neurology, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
E-mail werner_hacke@med.uni-heidelberg.de
© 2004 American Heart Association, Inc.
Stroke is available at http://www.strokeaha.org DOI: 10.1161/01.STR.0000149938.08731.2c
66
 at GLASGOW UNIV LIB on January 23, 2012http://stroke.ahajournals.org/Downloaded from 
Because of its high fibrin specificity, nonactivation by
-amyloid, and long terminal half-life, the plasminogen
activator recombinant Desmodus Salivary Plasminogen Ac-
tivator -1 (rDSPA -1 or desmoteplase) is an attractive
thrombolytic agent. Another possible advantage is the ab-
sence of neurotoxicity compared with rtPA.6–7
A common MRI profile in patients with AIS is an area of
perfusion deficit on perfusion MRI (pMRI) that is larger than
the lesion on diffusion-weighted imaging (DWI) that may
partly reflect irreversibly damaged brain tissue. This perfu-
sion/diffusion mismatch is believed to be a marker of sal-
vageable brain tissue (presumptive ischemic penumbra), pro-
vided that perfusion can be restored early enough.8–10 The
objective of the Desmoteplase In Acute Ischemic Stroke trial
(DIAS) was to explore the safety and efficacy of various
doses of IV desmoteplase in patients with AIS and perfusion/
diffusion mismatch on MRI up to 9 hours from stroke onset
to establish the optimal dose for further study.
Patients and Methods
Patients, Dosages, and Sample Size Calculation
Between January 2001 and October 2003, 44 centers in 12 countries
participated in this double-blind, placebo-controlled, randomized,
dose-finding, phase II trial of desmoteplase for treatment of AIS. The
protocol and all amendments received institutional review board
approval at each center and written informed consent was obtained
from all patients or their legal representative.
The original trial design planned to investigate 3 fixed doses of 25
mg, 37.5 mg, and 50 mg desmoteplase versus placebo in 4 parallel
groups of 30 patients each (hereafter called Part 1). These doses were
chosen based on safety findings from a preliminary trial in patients with
myocardial infarction, because they were not associated with fibrinogen
depletion. Trial drug was administered as an IV bolus over 1 to 2
minutes. Stratification according to age (75 versus 75) and baseline
National Institute of Health Stroke Scale (NIHSS;14 versus14) was
performed. Treatment allocation was performed through an interactive
voice response system collecting patient’s date of birth, weight, and
NIHSS score. Patients were randomized to a dose of desmoteplase or
placebo. Patients 66 kg were administered 80% of the dose, those
66kg received 100%. An independent Data Monitoring Committee
(DMC) monitored hemorrhages and other adverse events using prospec-
tively defined stopping rules.
After enrollment of the 30th patient, the occurrence of 3 symp-
tomatic intracranial hemorrhages (sICHs) in the 37.5 mg group and
1 in the 50 mg group resulted in discontinuation of these doses by the
DMC. The trial continued with 25 mg and placebo. After the 47th
patient was recruited, excess sICH rates in the 25-mg group
prompted a halt by the DMC, an interim analysis, and subsequent
protocol amendment.
The trial recommenced (Part 2) using a placebo-controlled
bodyweight-adjusted dose-escalation design starting at a dose of 62.5
g/kg, followed by 90 g/kg and 125 g/kg. Each dose tier included
15 desmoteplase patients and 4 placebo patients. No stratification
was implemented.
Inclusion and Exclusion Criteria
Eligible patients were aged 18 to 85 years, scored 8 to 20 on NIHSS,
showed at least 20% perfusion/diffusion mismatch (as evaluated by
visual inspection) involving hemispheric gray matter, and could be
treated within 3 to 6 hours after stroke onset. Exclusion criteria were
similar to those adopted by other thrombolytic trials. Several
adjustments in eligibility criteria were made during the course of the
trial.
1. After 5 patients were included in Part 1, a 30-minute MRI-to-
treatment time requirement was applied to minimize the pos-
sibility of spontaneous MRI changes between scan acquisition
and start of treatment. In addition, the upper limit for the DWI
lesion at baseline was reduced from two thirds to one third of
the middle cerebral artery (MCA) territory to limit the risk of
bleeding, and patients taking any platelet function inhibitor
were excluded if administering the trial medication might add
an additional risk of hemorrhage in the judgment of the
investigator.
2. To enhance recruitment, after the enrollment of 9 patients, the
baseline NIHSS range was extended from 8 to 20 to 4 to 20 and
the onset-to-treatment time window was widened from 3 to 6 to
3 to 9 hours. The selection of patients based on perfusion/
diffusion mismatch and DWI lesion size was considered a
theoretical safeguard allowing the expansion of the time
window.
3. After the interim analysis of Part 1, the upper limit of baseline
blood sugar was reduced from 22 to 11mmol/L because an
analysis of risk factors for ICH revealed an association with
blood glucose level 10mmol/L (Table 1).
MRI Examinations
MRI was performed at screening, 4 to 8 hours posttreatment, and 30
days follow-up. The screening and 4 to 8 hour MRI consisted of a
scout, single shot echo-planar DWI, 3D time-of-flight magnetic
resonance angiography (MRA) of the intracranial circulation, fluid-
attenuated inversion recovery (FLAIR), and bolus-tracking suscep-
tibility (T2*) weighted pMRI using intravenous gadolinium
0.1mmol/kg at 5cc/s. At 30 days, the MRI protocol was composed of
scout, DWI and FLAIR.
All MRI scanners used were 1.5 T equipped with manufacturer
head coils and echo-planar capability. Sequence parameters were
standardized across matched scanner types and trial centers. Images
were sent to a Core Imaging Laboratory (Perceptive) for processing
and analysis. Although different analytic methods for pMRI (eg,
mean transit time [MTT] and time-to-peak) were allowed at the
centers, MTT maps were created based on the normalized first
moment method at the Core Imaging Laboratory. Image analysis was
performed blinded to dose assignment, clinical information, and trial
center. In addition, the reader was blinded to the order of the baseline
and 4- to 8-hour scans. Image analysis included volume of abnor-
mality on DWI and MTT at baseline and 4 to 8 hours, volume of the
chronic lesion on FLAIR, and presence of ICH. The degree of
arterial stenosis or occlusion was also assessed, based on an
adaptation of the Thrombolysis In Myocardial Infarction grading
scheme: 0complete occlusion, 1severe stenosis, 2mild to
moderate stenosis, and 3normal arterial caliber. The full details of
MRI acquisition, analytic methods, and results will be the subject of
a separate communication.
Endpoints
The primary safety endpoint was the rate of sICH defined as any ICH
associated with a worsening of 4 points or more on the NIHSS and
confirmed by computerized tomography within 72 hours of treat-
ment. Other safety outcomes included major systemic bleeding,
anaphylaxis, and mortality. Other adverse events and serious adverse
events were also monitored.
The coprimary efficacy endpoints were reperfusion and clinical
outcome. Reperfusion was assessed 4 to 8 hours posttreatment and
defined as either 30% reduction of MTT volume of abnormality or
2 points improvement on the adapted Thrombolysis In Myocardial
Infarction grading scheme using MRA. The primary clinical end-
point was based on the combined analysis of the NIHSS, modified
Rankin scale (mRS), and Barthel Index (BI) defined as 8 points
improvement or scoring 0 to 1 on the NIHSS, a score of 0 to 2 on
mRS, and a BI score of 75 to 100 at 90 days. The clinical status of
the patient was also assessed at 4 to 8 hours, 7 days, and 30 days
using the same scales. Other efficacy outcome measures included the
change in infarct lesion volume on DWI from baseline to 30 days.
The DMC was immediately informed of each newly randomized
patient, any hemorrhages occurring after treatment, and about the
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72-hour outcome of each patient. The DMC was unblinded and not
involved in other trial tasks.
Statistical Analysis
Efficacy and safety analyses were performed for the intention-to-
treat sample. Deceased patients were given the worst possible
score for all outcomes. Other missing data were replaced by the
last observation carried forward. Exploratory analyses included
comparisons among the desmoteplase doses and between des-
moteplase and placebo regarding all safety and efficacy parame-
ters. Comparison of treatment groups was based on the odds ratio
method. All group comparisons with 1-sided probability values
TABLE 1. Patient Selection Criteria
Inclusion criteria
Age 18–85 y
Treatment onset within 3–9 h after stroke onset
Stable ischemic stroke scoring 4–20 on the NIHSS
MRI inclusion criteria
MRI screening to be started within 8 h after stroke onset
Perfusion abnormality of 2 cm in diameter involving hemispheric gray matter
Perfusion/diffusion mismatch of 20%
Exclusion criteria
Patients not eligible to receive trial medication within 30 min after completion of MRI
Females in the childbearing age (except those with hysterectomy)
Unknown stroke onset
Prestroke mRS of 1
History of ICH at any time, neoplasm, subarachnoid hemorrhage (SAH), arteriovenous malformation or
aneurysm
Clinical presentation suggestive of SAH even if MRI is normal
Current use of oral anticoagulants or a prolonged prothrombin time (International Normalized Ratio 1.7)
Use of heparin in the previous 48 h or a prolonged partial thromboplastin time (1.5control)
Current use of glycoprotein IIb-IIIa inhibitors
Conditions that, according to the judgment of the investigator, may impose an additional risk to any individual
stroke patient when receiving trial medication (this applies as well to patients on platelet-function inhibitors)
Platelet count 100 000/mm3
Hematocrit of 0.25
Blood glucose 50 mg/dL or 200 mg/dL (3 mmol/L or 11 mmol/L)
Pretreatment systolic blood pressure 185 mm Hg or diastolic blood pressure 110 mm Hg not responding to
intravenous antihypertensive therapy or requirement of aggressive treatment to reduce blood pressure to within
these limits (185/110 mm Hg)
Hereditary or acquired hemorrhagic diathesis
Gastrointestinal or urinary bleeding within the preceding 21 d
Arterial puncture in a noncompressible site within the previous 7 d
Another stroke or a serious head injury in the previous 3 mo
Major surgery within the preceding 14 d
Rapidly improving neurological signs
Seizure at the onset of stroke
Comatose patient
Myocardial infarction within the previous 3 weeks
Exposure to a thrombolytic within the previous 72 h
Previous participation in a desmoteplase trial
MRI exclusion criteria
Evidence of ICH
Evidence of SAH
DWI abnormality involving 1/3 of MCA territory
No perfusion deficit
Internal carotid artery occlusion ipsilateral to stroke lesion without additional ipsilateral middle, anterior, or
posterior cerebral artery occlusion
Any intracranial pathology interfering with the assessment of diffusion and perfusion abnormalities
Contraindications to MRI
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relating to /20.025 were hypothesis generating in nature. In
addition, 95% CI for proportions were computed. Because of the
small sample sizes, the data of the 37.5 mg and 50 mg groups
were pooled.
Concomitant Medication
In the first 24 hours after administration of trial medication,
anticoagulants and antiplatelet agents were not allowed for safety
reasons. Thereafter, these agents could be used at the discretion of
the investigator. The use of other thrombolytics was prohibited in the
first 72 hours.
Investigator and Center Qualification
Only certified trial staff were allowed to perform NIHSS assessment
on patients. Centers also had to qualify for the MRI procedures. Both
the MRI Committee and the Core Imaging Laboratory assisted in
designing the imaging protocol, recruiting centers with appropriate
MRI equipment, handling imaging problems arising from the cen-
ters, and monitoring compliance with MRI procedures.
Results
A total of 104 patients were randomized into DIAS: 47 in Part
1 and 57 in Part 2. Two patients, randomized to receive
placebo, received no trial medication because of the need for
arterial puncture in 1 patient and a different interpretation of
MRI findings after randomization for the other. Both patients
were excluded from all analyses. The desmoteplase and
placebo groups were balanced with regard to patient’s char-
acteristics, except for a longer time from onset in the 90
g/kg dose group and larger DWI lesion volumes in both the
90-g/kg and 125-g/kg dose groups (Table 2). Sixteen
patients terminated the study prematurely because of death
(n10), consent-withdrawal (n5), and loss to follow-up
(n1).
Part 1: Safety
Primary Safety Endpoint
sICHs were observed in 8 of 30 desmoteplase-treated patients
(26.7%), of which 4 of 17 were in the 25-mg group (23.5%)
and 4 of 13 in the 37.5/50-mg group (30.8%; Table 3). All
sICHs occurred within the first 24 hours after treatment
except one, which occurred at 25 hours. Protocol violations
occurred in 2 patients with sICH: one received heparin within
24 hours and the other had a high baseline blood glucose
level. No sICH occurred in placebo-treated patients. The high
sICH rates resulted first in the discontinuation of the 50 mg
and 37.5 mg doses and finally in trial suspension.
The desmoteplase dosages the patients received in Part 1
ranged from 227 g/kg to 714 g/kg when calculated on a
weight basis. The lowest dose associated with sICH was 294
g/kg.
Other Safety Endpoints
Mortality within 90 days was higher with active treatment.
Seven deaths occurred, all among desmoteplase-treated pa-
tients. Deaths were secondary to sICH (n4) or cardiopul-
monary causes (n3). Asymptomatic ICH occurred in 7
TABLE 2. Characteristics of Patients
Treatment Group
TotalPart 1 Part 2
Placebo
(n16)
25 mg*
(n17)
37.5/50 mg*
(n13)
Placebo
(n11)
62.5 g/kg*
(n15)
90 g/kg*
(n15)
125 g/kg*
(n15)
Placebo
(n27)
Desmoteplase
(n75)
Total
(n102)
Female, % 43.8 35.3 38.5 54.5 53.3 53.3 46.7 48.1 45.3 46.1
Age, y 67.5 65 72 70 70 69 70 68 68 68
NIHSS 12.5 11 11 8 13 12 12 12 12 12
Time from onset, min 320 330 310 340 360 400 295 325 324 325
DWI lesion volume, ml 14.99 14.49 16.86 29.73 23.83 53.38 49.78 20.40 17.76 17.88
Glucose level, mmol/L 6.53 6.83 6.88 6.90 6.38 6.50 6.20 6.60 6.77 6.69
All values are median values except for Female.
*Desmoteplase dose.
TABLE 3. Intracranial Hemorrhage
Treatment Group
TotalPart 1 Part 2
Placebo
(n16)
25 mg*
(n17)
37.5/50 mg*
(n13)
Placebo
(n11)
62.5 g/kg*
(n15)
90 g/kg*
(n15)
125 g/kg*
(n15)
Placebo
(n27)
Desmoteplase
(n75)
Total
(n102)
Asymptomatic ICH
No. (%) 2 (12.5) 3 (17.6) 2 (15.4) 3 (27.3) 5 (33.3) 3 (20.0) 6 (40.0) 5 (18.5) 19 (25.3) 24 (23.5)
95% CI 1.6; 38.3 3.8; 43.4 1.9; 45.4 6.0; 61.0 11.8; 61.6 4.3; 48.1 16.3; 67.7 6.3; 38.1 16.0; 36.7 15.7; 33.0
Symptomatic ICH
No. (%) 0 (0.0) 4 (23.5) 4 (30.8) 0 (0.0) 0 (0.0) 1 (6.7) 0 (0.0) 0 (0.0) 9 (12.0) 9 (8.8)
95% CI 0.0; 20.6 6.8; 49.9 9.1; 61.4 0.0; 28.5 0.0; 21.8 0.2; 31.9 0.0; 21.8 0.0; 12.8 5.6; 21.6 4.1; 16.1
*Desmoteplase dose.
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patients: 2 of 16 placebo-treated patients (12.5%) and 5 of 30
desmoteplase-treated patients (16.7%). Two desmoteplase-
treated patients (25 mg) experienced major gastrointestinal
hemorrhages, 1 on day 1 and 1 on day 63, and 1 placebo-
treated patient on day 27.
Part 1: Efficacy
Reperfusion
The 4 to 8 hours posttreatment magnetic resonance (MR)-
images of 1 desmoteplase-treated patient were missing. Early
reperfusion at 4 to 8 hours after treatment was observed in 9
of 16 patients receiving 25 mg desmoteplase (56.3%), 7 of 13
receiving 37.5/50 mg desmoteplase (46.2%), and 3 of 16
placebo-treated patients (18.8%; Table 4).
Primary Clinical Endpoint
A favorable clinical outcome at 90 days was achieved in 7 of
17 desmoteplase-treated patients in the 25-mg group (41.2%),
4 of 13 in the 37.5/50-mg group (30.8%), and in 4 of 16
placebo-treated patients (25.0%; Table 5).
Part 2: Safety
Primary Safety Endpoint
No placebo-treated patients and 1 of 45 desmoteplase-treated
patients (2.2%) had sICH; this patient received 90 g/kg
desmoteplase (Table 3).
Other Safety Endpoints
Three patients, 1 placebo-treated (9.1%) and 2 desmoteplase-
treated (4.4%), died because of cardiac causes. Asymptomatic
ICHs occurred in 17 patients (30.4%); 3 of 11 placebo-treated
patients (27.3%) and 14 of 45 desmoteplase-treated patients
(31.1%; Table 3). One major gastrointestinal hemorrhage
occurred in the 62.5-g/kg group on day 79.
Part 2: Efficacy
Reperfusion
MR-images of 3 desmoteplase-treated patients and 1 placebo-
treated patient were either missing or not assessable. Early
reperfusion at 4 to 8 hours after treatment was observed in 3
of 13 desmoteplase-treated patients in the 62.5-g/kg group
(23.1%), 7 of 15 in the 90-g/kg group (46.7%), 10 of 14 in
the 125-g/kg group (71.4%), and in 2 of 10 placebo-treated
patients (20%; Table 4 and Figure 1).
Primary Clinical Endpoint
There was a dose-dependent rate of favorable outcome at 90
days, with 13.3%, 46.7%, and 60% of patients in the
62.5-g/kg, 90-g/kg, and 125-g/kg desmoteplase groups,
respectively, showing a favorable clinical outcome compared
with 18.2% in the placebo group (Table 5 and Figure 1).
Pooling placebo-treated patients from both Part 1 and Part
2 showed a reperfusion rate of 19.2% and a favorable clinical
response in 22.2%. Compared with pooled placebo, the
125-g/kg desmoteplase dose achieved significantly better
results (reperfusion P0.0012; favorable clinical outcome
P0.0090).
Other Analyses
In the 97 patients with assessable MR-images, a favorable
clinical outcome at 90 days was achieved in 21 of 40 patients
with reperfusion (52.5%) and 14 of 57 without reperfusion
(24.6%). There was a significant correlation between reper-
fusion and favorable clinical outcome (P0.0028). In pa-
TABLE 4. Reperfusion on MRI at 4 to 8 Hours After Treatment Onset*
4 to 8 h
Reperfusion
Treatment Group
TotalPart 1 Part 2
Placebo
(n16)
25 mg†
(n16)
37.5/50 mg†
(n13)
Placebo
(n10)
62.5 g/kg†
(n13)
90 g/kg†
(n15)
125 g/kg†
(n14)
Placebo
(n26)
Desmoteplase
(n71)
Total
(n97)
No. (%) 3 (18.8) 9 (56.3) 6 (46.2) 2 (20.0) 3 (23.1) 7 (46.7) 10 (71.4) 5 (19.2) 35 (49.3) 40 (41.2)
95% CI 4.0; 45.6 29.9; 80.2 19.2; 74.9 2.5; 55.6 5.0; 53.8 21.3; 73.4 41.9; 91.6 6.6; 39.4 37.2; 61.4 31.3; 51.7
P values‡ 0.0086 0.0431 0.3897 0.0349 0.0012 0.0054
*All patients with assessable images.
†Desmoteplase dose.
‡vs placebo total.
TABLE 5. Favorable Clinical Outcome at 90 Days*
Favorable
Clinical
Outcome
Treatment Group
TotalPart 1 Part 2
Placebo
(n16)
25 mg†
(n17)
37.5/50 mg†
(n13)
Placebo
(n11)
62.5 g/kg†
(n15)
90 g/kg†
(n15)
125 g/kg†
(n15)
Placebo
(n27)
Desmoteplase
(n75)
Total
(n102)
No. (%) 4 (25.0) 7 (41.2) 4 (30.8) 2 (18.2) 2 (13.3) 7 (46.7) 9 (60.0) 6 (22.2) 29 (38.7) 35 (34.3)
95% CI 7.3; 52.4 18.4; 67.1 9.1; 61.4 2.3; 51.8 1.7; 40.5 21.3; 73.4 32.3; 83.7 8.6; 42.3 27.6; 50.6 25.2; 44.4
P values‡ 0.0925 0.2801 0.7568 0.0535 0.0090 0.0640
*8 points improvement on NIHSS (or 0 to 1), mRS (0 to 2), and BI (75 t0 100).
†Desmoteplase dose; ‡vs placebo total.
70 Stroke January 2005
 at GLASGOW UNIV LIB on January 23, 2012http://stroke.ahajournals.org/Downloaded from 
tients with no reperfusion by MRI criteria, 12 of 36
desmoteplase-treated patients (33.3%) and 2 of 21 placebo-
treated patients (9.5%) had a favorable clinical outcome.
Among the desmoteplase-treated patients with no reperfusion
by MRI criteria, those in the 90-g/kg and 125-g/kg groups
achieved the highest favorable clinical outcome rates (50%
each), whereas the 62.5-g/kg group showed the lowest
(10%).
Treatment with desmoteplase within 3 to 6 hours after
symptom onset displayed a favorable clinical outcome at
90 days in 18 of 47 patients (38.3%). After 6 hours, 11 of
28 desmoteplase-treated patients (39.3%) showed a favor-
able clinical outcome. Reperfusion on MRI was achieved
in 25 of 46 patients treated with desmoteplase within 3 to
6 hours after symptom onset (54.3%) and in 10 of 25 after
6 hours (40.0%).
In univariate analysis of patient’s characteristics (Figure 2),
the important risk factors for any ICH were high NIHSS
score, large DWI lesion volume, and high glucose level at
baseline. Age 68 years appeared more predictive for sICH.
The only parameter that reached statistical significance for
sICH was desmoteplase dose. There was no difference in
sICH rates in patients treated 3 to 6 hours versus 6 to 9 hours.
Other than major hemorrhages, the most common serious
adverse events were neurological complications, cardiac dis-
orders, and respiratory disorders. Their frequency was 13.3%,
9.3%, and 6.7% in the desmoteplase-treated patients and
22.2%, 3.7%, and 3.7% in the placebo-treated patients,
respectively. No anaphylactic reactions occurred.
Discussion
DIAS is the first prospective, placebo-controlled randomized
acute stroke thrombolysis trial to use MRI both for patient
selection and as a primary efficacy endpoint. The trial used a
predefined lesion pattern (perfusion/diffusion mismatch) as
an inclusion criterion and tested whether dose-dependent IV
desmoteplase safely improves reperfusion between 3 and 9
hours from stroke onset.
In preclinical studies, desmoteplase demonstrated high
fibrin specificity and selectivity, nonactivation by -amyloid,
a long half-life, and absence of neurotoxicity. These are
potential advantages over other thrombolytic agents including
rtPA. Desmoteplase has also been tested in a phase II trial in
patients with myocardial infarction, where doses of 500
g/kg and 750 g/kg confirmed thrombolytic activity in
humans without causing fibrinogen depletion. DIAS therefore
began with a dose-ranging design investigating fixed doses
between 25 mg (median313 g/kg) and 50 mg (medi-
an546 g/kg). However, these doses were associated with
excessive sICH. Reducing the size of the qualifying DWI
abnormality from a maximum of two thirds to one third of the
MCA territory after 5 patients were treated did not produce
any demonstrable decrease in the rate of sICH. Despite the
high rate of sICH in Part 1, efficacy analyses suggested
favorable trends in reperfusion rates and clinical outcome,
and subsequent calculations based on the pharmacokinetics of
desmoteplase indicated that doses lower than those tested
might be safer and effective. The revised design Part 2 tested
lower weight-adjusted doses of desmoteplase and confirmed
that the high initial doses were the likely cause of the
excessive rates of sICH in Part 1. Part 2 showed a favorable
safety profile for the doses tested, with only 1 sICH among 45
desmoteplase-treated patients.
The MRI reperfusion rates of 46.7% and 71.4% at 4 to 8
hours after treatment with 90 g/kg and 125 g/kg of
desmoteplase suggest a dose-dependent effect of desmote-
plase and are supported by 90-day clinical response rates of
46.7% and 60%, respectively. Patients treated with 125 g/kg
of desmoteplase had better reperfusion and clinical response
rates than the combined high-dose treatment groups (25 to 50
mg) from Part 1, which may reflect improved safety at this
dose. The 62.5-g/kg dose did not cause significant
reperfusion.
The presence of larger baseline DWI lesions clustered in
the 90-g/kg and 125-g/kg dose groups may have disad-
vantaged the desmoteplase groups; other baseline factors
were reasonably balanced. The dose escalation design used in
Part 2 generated a small risk that the central interpretation of
MRI perfusion data could be influenced by knowledge of the
likely dose group, although treatment allocation remained
blinded.
A longer stroke onset to treatment interval was not asso-
ciated with a reduction of treatment effect, which suggests
that beyond 3 hours from onset of stroke the presence of
perfusion/diffusion mismatch as a marker of tissue at risk
may be a more important predictor of therapeutic response
than duration of symptoms.
There was also a positive correlation (P0.0028) between
reperfusion and clinical outcome. These findings are in line
with a recent report of patients receiving IV rtPA, which
found that a decrease in the volume of pretreatment MTT
defect of 30% 2 to 3 hours after treatment was a highly
significant predictor of clinical recovery (mRS 0 or 1).11
Among patients with no reperfusion on MRI, there was a
50% favorable outcome rate in both the 90-g/kg and
125-g/kg dose groups compared with 10% in the 62.5-
g/kg group. The rate in the placebo group was 9.5%. A
Figure 1. Reperfusion and favorable clinical outcome rates in
Part 2. *Desmoteplase dose in g/kg.
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possible explanation could be that the long half-life of
desmoteplase may have facilitated reperfusion after the 4 to 8
hour follow-up MRI scan in the 90-g/kg and 125-g/kg
dose groups, whereas the low rate in the 62.5-g/kg group
further indicates the noneffectiveness of this dose.
In using a thrombolytic drug safely, one of the most
important factors is the selection of patients with a low
inherent risk of spontaneous hemorrhagic transformation.
DIAS has confirmed that stroke severity and increasing age
are important predictors of sICH but did not establish severity
or age cutoff criteria beyond which treatment was unsafe.12–13
Mortality after desmoteplase was low and comparable to
placebo in Part 2. In contrast to the pooled analysis of the
ATLANTIS, ECASS and NINDS trials, which showed a
constant risk of ICH over the first 5 hours after stroke onset
with increasing risk in the 6th hour, DIAS found no time
dependency of sICH risk comparing patients treated  or 5
hours from stroke onset.5
In conclusion, DIAS suggests that IV thrombolysis with
desmoteplase 3 to 9 hours after stroke onset is safe in patients
selected according to perfusion/diffusion mismatch on MRI
and that dose dependent reperfusion on MRI is correlated
with clinical outcome. Patients treated with desmoteplase
between 6 and 9 hours of stroke onset had a clinical outcome
that was as good as those treated within 3 to 6 hours. This
finding supports the concept of shifting from a general
ticking-clock to an individualized tissue-clock in ischemic
stroke. However, all these findings need to be confirmed and
studied in larger trials.
Appendix
The following centers recruited patients to DIAS (center, principal
investigator, and number of patients): Heidelberg, Germany: Hacke
and Ringleb (17); Leipzig, Germany: Schneider (11); Lausanne,
Switzerland: Bogousslavsky (10); Girona, Spain: Davalos (9); Ham-
burg, Germany: Weiller (9); Linz, Austria: Aichner (7); Bordeaux,
France: Rouanet (6); Paris, France: Chabriat (6); Singapore: Chang
(5); Graz, Austria: Fazekas (3); Ulm, Germany: Huber (3); Paris,
France: Touze´ (2); St Gallen, Switzerland: Weder (2); Munich,
Germany: Sander (2); Melbourne, Australia: Davis (1); New Lamb-
ton Heights, Australia: Levi (1); Brussels, Belgium: Blecic (1);
Helsinki, Finland: Kaste (1); Lyon, France: Trouillas (1); Paris,
France: Samson (1); Bochum, Germany: Meves (1); Frankfurt,
Germany: Steinmetz (1); Freiburg, Germany: Hetzel (1); Bergen,
Norway: Thomassen (1); Badalona, Spain: Vila (1); and Aberdeen,
Great Britain: MacLeod (1).
Steering Committee: Werner Hacke (Chair), Anthony Furlan,
Markku Kaste, Michael Eliasziw, Michael Fischer, Mariola Soehn-
gen, and Yasir Al-Rawi. Greg Albers participated in Part 1 of DIAS.
Figure 2. Potential risk factors for ICH.
sICH indicates symptomatic ICH; aICH,
asymptomatic ICH. *Cut point is the
median for all patients treated, n102.
†Only desmoteplase-treated patients.
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MRI Committee: Steven Warach (Chair), Julien Bogousslavsky,
and Howard Rowley. Marc Fisher participated in Part 1 of DIAS.
DMC: Kennedy Lees (Chair), Lawrence Wechsler, Ru¨diger von
Kummer, and Walter Lehmacher. Claus-Steffen Stuerzebecher and
Klaus Poeck participated in Part 1 of DIAS.
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